LOTRISONE
LOE ApproachingNDATOPICALLOTION
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOTRISONE is a topical lotion combination product marketed by Merck & Co. since December 2000. The specific active ingredients and mechanism of action are not detailed in available data, but topical lotions in dermatology typically address inflammatory skin conditions. This product represents a mature, branded topical formulation in a competitive dermatology market.
LOE Approaching
As LOE approaches, the brand team is likely consolidating to protect market share against generics; commercial headcount may shift toward line extensions or new formulations rather than growth activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LOTRISONE currently shows zero linked job openings, reflecting its LOE-approaching status and mature lifecycle stage. Career opportunities on this product are limited to defensive commercialization and market access roles focused on protecting existing market position.
Brand ManagerField Sales Representative
Worked on LOTRISONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.